LinkedIn facebook twitter youtube
News archive
Recent news

The European Medicines Agency is currently inviting one or two myeloma patients to participate in a discussion and oral explanation about a potential medicine to treat the disease during the COMP meeting in January (Committee for Orphan Medical Products).

The discussions relates to an orphan designation for a potential drug to treat multiple myeloma and the patients designated will be able to contribute from a patient perspective.

The session will take place on 19 January 2016 and the Agency will cover travel and accommodation costs. As for all experts, the patients designated to attend would need to complete a confidentiality agreement / declaration of interests form which will be assessed beforehand. All participants must be myeloma patients with a fluent English level to take part in the conversation.

If you would like to participate, please fill in the form below before 22 December.

[contact-form-7 id=”1267″ title=”COMP meeting”]

Recent news

» Melflufen receives positive opinion from the European Medicines Agency (EMA) for the treatment of refractory myeloma

» EHA 2022 highlights in myeloma and AL amyloidosis

Leave a Reply

Your email address will not be published.

I accept the Privacy Policy